An exon-skipping medicine for Duchenne muscular dystrophy
Eteplirsen
A specialist medicine for Duchenne muscular dystrophy in people whose gene change is suited to skipping exon 51.
What is Eteplirsen?
Eteplirsen is a specialist medicine used to treat Duchenne muscular dystrophy, an inherited muscle-weakening condition that mainly affects boys. It only suits people whose specific genetic change can be helped by 'skipping' a particular part of the gene called exon 51, so genetic testing is done first. It works by helping the body make a shortened but more useful form of a muscle protein called dystrophin. It is given as an infusion into a vein, usually weekly. It is generally well tolerated, with infusion-related reactions being the main thing watched for. It is a specialist treatment, not a cure.
Education and reference only. This is a plain-language guide to Eteplirsen — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Eteplirsen is a specialist medicine used to treat Duchenne muscular dystrophy, an inherited condition, mostly affecting boys, in which muscles gradually weaken because the body cannot make a protein called dystrophin properly. It is one of a group of 'exon-skipping' medicines and only works for people whose particular genetic change is suited to skipping a section of the gene called exon 51, which is confirmed by genetic testing first. It is given as an infusion into a vein, usually once a week, under the care of a specialist team.
How it works
In Duchenne muscular dystrophy, a fault in the dystrophin gene stops the body making working dystrophin, a protein that helps protect muscle fibres. Eteplirsen works by helping the cell's machinery 'skip over' a faulty section of the gene (exon 51) when the protein is being made. This lets the body produce a shorter, but partly working, form of dystrophin instead of none at all, which is intended to slow the loss of muscle strength. Because it only addresses gene changes suited to skipping exon 51, it is used only after genetic testing confirms this.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist medicine used in some countries for Duchenne muscular dystrophy in boys whose genetic change can be helped by skipping a particular part of the gene (exon 51).
Practical use
How to take Eteplirsen
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- Attend for the infusion into a vein as scheduled, usually once a week.
- Make sure genetic testing has confirmed your change is suited to exon 51 skipping, as it only works in that case.
- Report any reaction during or after the infusion, such as flushing, rash or feeling unwell.
- Keep up your other Duchenne care, such as physiotherapy and other treatments, as this is one part of overall care.
- Tell your team about all your other medicines and any allergies before treatment.
Weighing it up
Advantages & disadvantages of Eteplirsen
Advantages
- Aims to help the body make a partly working form of dystrophin to slow muscle weakening.
- Generally well tolerated, with infusion-related reactions being the main thing watched for.
- Targets the underlying genetic cause in people suited to exon 51 skipping.
Disadvantages
- Only works for people whose genetic change is suited to skipping exon 51, so testing is needed first.
- Given as a weekly infusion into a vein, often over many years.
- Aims to slow the condition rather than cure it, so it is one part of overall care.
Practical use
Good to know
Eteplirsen only helps people whose specific genetic change is suited to skipping exon 51, so genetic testing is essential before starting, and it will not work for other genetic changes. It is given as a weekly infusion into a vein, so part of treatment is attending regularly for the infusion, often over many years. Reassuringly, it is generally well tolerated, and the main thing watched for is reactions related to the infusion itself, such as flushing, rash or feeling unwell, which the team monitors for. It is used as one part of overall Duchenne care, alongside physiotherapy and other treatments, and it is a treatment that aims to slow the condition rather than a cure, so realistic expectations are important.
Who should not take it / use with caution
- People who have had a serious allergic reaction to eteplirsen should not have it.
- It will not help people whose genetic change is not suited to exon 51 skipping.
- It should only be used under a specialist neuromuscular service, with monitoring during infusions.
Monitoring
- Confirming the genetic change is suited to exon 51 skipping before starting.
- Watching for reactions during and after infusions.
- Reviewing muscle strength and function over time as part of overall care.
Side effects
- It is generally well tolerated, with many people having few side effects.
- Reactions related to the infusion, such as flushing, rash or feeling unwell.
- Balance problems, vomiting or skin reactions in some people.
- Rarely, more troublesome reactions, which should be reported to the team.
Key interactions
- There are few well-established routine medicine interactions, but tell your team about all your medicines.
- Any history of allergy or previous infusion reactions should be shared before treatment.
- It is used alongside, not instead of, other Duchenne care such as physiotherapy.
Available as: A solution for infusion into a vein, usually given weekly.
Answers
Eteplirsen: frequently asked questions
What is eteplirsen used for?
It is used to treat Duchenne muscular dystrophy in people whose specific genetic change is suited to 'skipping' a part of the gene called exon 51.
Why is genetic testing needed first?
Eteplirsen only works for certain genetic changes that are suited to exon 51 skipping, so a genetic test is done first to confirm it is the right treatment.
How does it work?
It helps the body's machinery skip over a faulty part of the gene, so a shorter but partly working form of the muscle protein dystrophin can be made.
How is it given?
It is given as an infusion into a vein, usually once a week, under the care of a specialist neuromuscular team.
Is it a cure?
No. It aims to slow the loss of muscle strength and is used as part of overall Duchenne care, including physiotherapy; it is not a cure.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.